Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures

A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures

Zonisamide is already marketed for the treatment of partial seizures in epilepsy. This study is intended to provide evidence that zonisamide is safe and effective in the treatment of primary generalised tonic-clonic seizures. The total trial duration will be 5.5-6.5 months. After that subjects who have completed the study will be eligible to enrol in an open-label extension study until zonisamide is marketed for this indication or further development in this indication stops. This extension study will be described in a separate protocol (E2090-E044-316).

Study Overview

• Status: Terminated
• Conditions: Epilepsy
• Intervention / Treatment: Drug: Zonisamide; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Melbourne, Australia
    • St. Vincents Hospital
  • New South Wales
    • Chatswood, New South Wales, Australia, 2067
      • Strategic Health Evaluators Pty Ltd
    • Randwick, New South Wales, Australia, 2031
      • The Prince of Wales Hospital
  • Victoria
    • Heidelburg, Victoria, Australia, 3084
      • Austin Health
    • Melbourne, Victoria, Australia, 3050
      • The Royal Melbourne Hospital
• Croatia
  • HR
    • Split, HR, Croatia, 10000
      • CH Split
    • Zagreb, HR, Croatia, 10000
      • UHC Zagreb
    • Zagreb, HR, Croatia, 10000
      • CH Sestre Milosrdnice University Hospital
• Czech Republic
  • Hradec Kralove, Czech Republic, 500 03
    • Neurologicke oddeleni
  • Kromeriz, Czech Republic, 767 01
    • Private Neurologi Office
  • Olomouc, Czech Republic, 775 20
    • Fakultni Nemocnice Olomouc
  • Ostrava, Czech Republic, 708 52
    • Fakultni nemocnice s poliklinikou Ostrava
  • Plzen, Czech Republic, 305 99
    • Fakultni nemocnice Plzen
  • Praha 5, Czech Republic, 150 30
    • Nemocnice Na Homolce
  • Rychnov nad Kneznou, Czech Republic, 516 01
    • Centrum neurologicke pece
• Estonia
  • Tallinn, Estonia, 10611
    • West-Tallinn Central Hospital
  • Tallinn, Estonia, 11312
    • Neurodiagnostica AP OY
  • Tartu, Estonia, 51014
    • Tartu University Hospital
• Finland
  • Oulu, Finland, 90220
    • Oulu University Central Hospital
  • SF
    • Kuopio, SF, Finland, 70211
      • Kuopio Epilepsy Center
• Germany
  • Berlin, Germany, 10365
    • Institut fur Diagnostik der Epilepsien
  • Freiburg, Germany, 79106
    • Neurochirurgische Klinik der Universitat Freiburg
  • Marburg, Germany, 35039
    • Interdisziplinares Epilepsiezentrum am Klinikum der Philipps-Universitat Marburg
  • Munchen, Germany, 80333
    • Neurologische Gemeinschaftspraxis
  • Ulm, Germany, 89081
    • Universitatsklinikum Ulm
• Hungary
  • Budapest, Hungary, 1021
    • National Institute of Psychiatry and Neurology
  • Budapest, Hungary, 1089
    • Heim Pal Hospital
  • Budapest, Hungary, 1091
    • Szent Istvan Hospital
  • Budapest, Hungary, 1145
    • Országos Idegsebészeti Tudományos Intézet
  • Budapest, Hungary, 1146
    • Bethesda Hospital for Children
  • Gyula, Hungary, 5703
    • Bekes County Pandy Kalman Hospital
  • Kecskemet, Hungary, 6000
    • Bacs-Kiskun County ONK Hospital
  • Szombathely, Hungary, 9400
    • Vas County Markusovszky Hospital
  • Veszpem, Hungary, 8200
    • Veszpem County Csolnoky F. Hospital
• Lithuania
  • Kaunas, Lithuania, 50009
    • Kaunas Medical University Hospital
  • Kaunas, Lithuania, 50185
    • Neuromeda
  • Vilnius, Lithuania, 8661
    • Vilnius University Hospital Santariskiu Klinikos
• Poland
  • Bialystok, Poland, 15-420
    • Niepubliczny ZOZ KENDRON
  • Gdansk, Poland, 80-803
    • Wojewodzki Szpital Specjalistyczny im. M. Kopernika
  • Katowice, Poland, 40-635
    • Specjalistyczny Szpital Wieloprofilowy
  • Krakow, Poland, 31-530
    • Centrum Neurologii Klinicznej
  • Lodz, Poland, 93-513
    • Szpital im. M. Kopernika
  • Poznan, Poland, 60-355
    • Uniwersytet Medyczny
• Romania
  • Bucharest, Romania, 050098
    • Spitalul Universitar de Urgenta Bucuresti
  • Bucharest, Romania, 041914
    • Spitalul Clinic de Psihiatrie
  • Bucharest, Romania, 11025
    • Centrul Medical Sana
  • Cluj-Napoca, Romania, 400006
    • Spitalul Clinic Judetean de Urgenta Cluj
  • Iasi, Romania, 700111
    • Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi
  • Iasi, Romania, 700309
    • Spitalul Clinic de Urgenta Sfanta Treime
  • Tg Mures, Romania, 540136
    • Spitalul Clinic Judetean de Urgenta Tg Mures
• Russian Federation
  • Krasnoyarsk, Russian Federation, 660022
    • GOU VPO Krasnoyarskaya State Medical Academy of Roszdrav
  • Moscow, Russian Federation, 107076
    • FGU Moscow Research Institute of Psychiatry of Roszdrav
  • Moscow, Russian Federation, 117997/119034
    • GOU VPO Russian State Medical University of Roszdrav
  • Moscow, Russian Federation, 119049
    • GOU VPO Smolensk State Medical Academy of Roszdrav
  • Moscow, Russian Federation, 127473 / 107006
    • GOU VPO Moscow State University of Medicine and Dentistry of Roszdrav
  • Novosibirsk, Russian Federation, 630091
    • GOU VPO Novosibirsk State Medical University of Roszdrav
  • Smolensk, Russian Federation, 214018
    • GOU VPO Smolensk State Medical Academy of Roszdrav
  • Smolensk, Russian Federation, 214019
    • GOU VPO Smolensk State Medical Academy of Roszdrav
  • St. Petersburg, Russian Federation, 194100
    • St. Petersburg State Medical Pediatric Academy
  • St.Petersburg, Russian Federation, 192019
    • GU St. Petersburg Research Institute of Psychoneurology
  • St.Petersburg, Russian Federation, 197022
    • GOU VPO St. Petersburg State Medical University
  • Yaroslavl, Russian Federation, 150000
    • Yaroslavskaya State Medical Academy
• Serbia
  • Belgrade, Serbia, 11000
    • Clinical Center of Serbia
  • Belgrade, Serbia, 11000
    • University Medical Center Zvezdara
  • Kragujevac, Serbia, 34000
    • Clinical Center Kragujevac
  • Nis, Serbia, 18000
    • Clinical Center of Nis
• Ukraine
  • Dniepropetrovsk, Ukraine, 49005
    • Tsentr Psihosomatychnoyi Patologiyi Dnipropetrovskoyi oblasnoyi klinichnoyi likarni imeni Mechnikova
  • Kharkiv, Ukraine, 61068
    • Derzhavna Ustanova Institut Nevrologiy
  • Kyiv, Ukraine, 2660
    • Kyiv City Psychiatric Hospital #2, Poliklinichne Viddilenya
  • Kyiv, Ukraine, 3080
    • Miska Klinichna psihonevrologichna Tsentr Epilepsiyi
  • Lviv, Ukraine, 7910
    • Lvivskyiy oblasnyi Protyepileptuchnyy tsentr
  • Odesa, Ukraine, 65006
    • Odesskyy Derzhavnyy Medychnyy Universitet
  • Vinnitsa, Ukraine, 21005
    • Vinnitskyy Natsionalnyy Medychnyy Universitet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years to 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject is male or female and aged 6-65 years.
2. Subject has ≥ 3 PGTCS over the two months before screening and during the eight weeks Baseline Period with at least one seizure in each one month period. PGTCS must occur in the context of Idiopathic Generalized Epilepsy (IGE) and may be accompanied by other primary generalized seizures, provided these are also consistent with a diagnosis of IGE.
3. Subject (or parent/caregiver, for subjects below the age of consent) is willing to sign an informed consent form. For subjects below the age of consent in their country, where appropriate they must be willing to give informed (written or verbal) assent. Subjects from the age specified in local regulations will be required to sign an appropriate informed consent form.
4. Subject is taking a stable regimen of one or two other Antiepileptic Drugs (AEDs) for at least two weeks prior to Visit 1 (start of the Baseline Period).
5. Subject has a clinical diagnosis of any type of idiopathic generalized epilepsy which has PGTCS (and which may be accompanied by other generalized seizure types), according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures (1981) and the ILAE Classification of Epilepsies and Epileptic Syndromes (1989). Diagnosis should have been established by clinical history, electroencephalogram (EEG) and computed tomography/magnetic resonance imaging (CT/MRI) of the brain consistent with idiopathic generalized epilepsy. CT/MRI scan should have been performed within five years of the screening visit or, if not available from this period, should be performed in the Baseline Period.
6. EEG should have been performed within one year of the screening visit or, if not available from this period, should be performed in the Baseline Period.
7. Female subjects are pre-menarchal, or if of childbearing potential, are not pregnant or lactating or are post-menopausal.
8. Female subjects of childbearing potential must abide by the one of the following medically acceptable contraceptive measures: oral contraception pill, contraceptive injections, implants or patches, intrauterine device in place for at least three months or vasectomised partner or abstinence throughout the study.
9. Subject has a body weight ≥ 20 kg.

Exclusion Criteria:

1. Subject has progressive or focal neurological disease (as determined by pre-existing brain imaging such as CT or MRI performed maximally five years before the screening visit), or clinically significant organic disease.
2. Subject has a history of, or results of clinical investigations (including EEG data) that are suggestive of, partial seizures as defined by the ILAE, including generalized tonic clonic seizures which are suspected to be secondarily generalized.
3. Subjects with cryptogenic or symptomatic generalized epilepsy.
4. Subjects with psychogenic seizures.
5. Subject has a history of status epilepticus within a year of screening while complying with AEDs.
6. Subject has seizures that only occur in clustered patterns.
7. Subject has a history of renal calculi or renal insufficiency (above the upper normal limits of creatinine).
8. Subject has a known diagnosis of human immunodeficiency virus (HIV) or hepatitis B or C.
9. Subject had a predisposing condition that might interfere with absorption, distribution, or excretion of zonisamide.
10. Subject has a history of sensitivity to sulfonamide drugs or zonisamide and its excipients.
11. Subject has a recent history of excessive alcohol use or drug abuse.
12. Subject has a history of suicide attempt in the five years before the screening visit..
13. Subject has abnormal screening laboratory values that were clinically significant.
14. Subject has a history of demonstrated non-compliance with treatment or the subject or parent/caregiver can be reasonably expected not to be compliant with study procedures or to complete the study.
15. Subject has participated in a study of an investigational drug or device within 30 days prior to screening.
16. Subject has received previous treatment with zonisamide.
17. Subject is treated with ketogenic diet or vagus nerve stimulator.
18. Subject has a history of necessary treatment with rescue benzodiazepines which is foreseen to continue during the study. Rescue benzodiazepines will not be allowed in this study (stable dosing with a benzodiazepine as (one of the) baseline anti-epileptic drug(s) is allowed).
19. Current psychosis or moderate to severe depression, or use of anti-psychotic drugs, MAOIs, tricyclic antidepressants, benzodiazepine or barbiturate treatment for disorders other than epilepsy, and stimulants (amphetamine derivatives) within 28 days before the screening visit.
20. Concomitant use of acetazolamide, carbonic anhydrase inhibitors such as topiramate and drugs with anticholinergic activity.
21. Concomitant use of felbamate or use of felbamate within two months prior to Visit 1.
22. Subject is not able to swallow capsules.
23. Subject is not in general good health as determined by medical history, physical exam and screening laboratory results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; 25-400 mg Zonisamide Placebo capsules orally once daily in the evening. Maximum study duration of 28 weeks comprising: Baseline Period (Week-8/-4 to Week 0) no treatment Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4 Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events) Down Titration Period (4 weeks)
Active Comparator: Zonisamide	Drug: Zonisamide; 25-400 mg capsules orally once daily in the evening. Maximum study duration of 28 weeks comprising: Baseline Period (Week-8/-4 to Week 0) no treatment Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4 Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events) Down Titration Period (4 weeks); Other Names: Zonegran

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Considered Responders as Assessed During the Maintenance Period	The number of participants who were considered responders during the 12 week Maintenance Period (Week 4 to Week 16). A responder was defined as a participant with a decrease from baseline in Primary Generalised Tonic-Clonic Seizures (PGTCS) frequency of >= 50% (i.e. 28-day PGTC seizure frequency in the period from Week 4 to the Week 16 visit compared to Week -8/-4 to randomization at Week 0). Each participant's response to treatment was assessed on the basis of their seizure diaries. The diary was dispensed at the Screening Visit and maintained by the participant (parent/caregiver) through out the titration and maintenance treatment periods until the Early termination Visit at Week 16. Due to early termination of the study by the Sponsor, no formal analyses were conducted.	Baseline (Week -8/-4 to Week 0) and Maintenance Phase (Week 4 to Week 16)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute Change From Baseline in 28-day PGTC Seizure Frequency	Absolute Change from Baseline in 28-day PGTC Seizure Frequency was assessed both for the Maintenance Period alone (Week 4 to Week 16) and for the entire double-blind treatment period (Week 0 to Week 16). Due to early termination of the study by the Sponsor, no formal analyses were conducted.	Baseline and up to 16 weeks

Collaborators and Investigators

• Sponsor: Eisai Limited
• Investigators: Study Director: Rob Van Maanen, Eisai Limited

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2008
• Primary Completion (Actual): November 1, 2008
• Study Completion (Actual): January 9, 2009

Study Registration Dates

• First Submitted: June 3, 2008
• First Submitted That Met QC Criteria: June 5, 2008
• First Posted (Estimate): June 6, 2008

Study Record Updates

• Last Update Posted (Actual): March 14, 2017
• Last Update Submitted That Met QC Criteria: February 1, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Seizures; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Membrane Transport Modulators; Anticonvulsants; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Zonisamide
• Other Study ID Numbers: E2090-E044-315; Eudra ID #2007-003557-91.